Kaneko Y, Imoto S, Fukuda K, Kasakura S
Department of Clinical Pathology, Kobe City General Hospital.
Rinsho Byori. 1990 Jun;38(6):699-702.
We studied the false positive phenomena in immunoassay of CA 125 using mouse monoclonal antibody, and studied the natures of interfering substances. The serum CA 125 level in 405 patients was determined simultaneously by using the EIA and RIA methods. The overall correlation was good between CA 125 levels of the EIA and RIA methods. However, CA 125 levels in 41 cases were remarkably higher in the EIA method as compared with the RIA method. None of these patients had any disease that was known to result in elevation of the serum CA 125 level. The CA 125 activity of sera from five patients with remarkably discrepant values was contained in the column fractions corresponding to a molecular weight of human IgM in gel chromatography of TSK gel G 4000 SWXL that was smaller than the molecular weight of CA 125. To further determine whether IgM was involved in the CA 125 activity, we investigated the effect of adding anti-human IgM serum to discrepant sera. CA 125 activity was markedly reduced by the antiserum, whereas CA 125 activity in non-discrepant sera were not effected by this antiserum. Thus, data obtained from this group of experiments indicate that the interfering material in discrepant serum is IgM.
我们研究了使用小鼠单克隆抗体进行CA 125免疫测定时的假阳性现象,并研究了干扰物质的性质。采用酶免疫分析(EIA)和放射免疫分析(RIA)方法同时测定了405例患者的血清CA 125水平。EIA法和RIA法测定的CA 125水平总体相关性良好。然而,41例患者的CA 125水平在EIA法中显著高于RIA法。这些患者均无已知会导致血清CA 125水平升高的疾病。在TSK凝胶G 4000 SWXL凝胶色谱中,5例值差异显著患者血清的CA 125活性包含在对应于人类IgM分子量的柱级分中,该分子量小于CA 125的分子量。为了进一步确定IgM是否参与CA 125活性,我们研究了向差异血清中添加抗人IgM血清的效果。抗血清使CA 125活性显著降低,而非差异血清中的CA 125活性不受该抗血清影响。因此,从这组实验获得的数据表明,差异血清中的干扰物质是IgM。